Factors Associated with Recurrence Within 2 Years After Curative Surgery for Gastric Adenocarcinoma
Overview
Authors
Affiliations
Background: Despite curative surgery for gastric cancer, many patients die of recurrent cancer. Few studies have investigated the time to recurrence after curative resection for gastric cancer.
Methods: Data were collected prospectively between December 1987 and December 2006. A total of 1,549 patients underwent curative resection of adenocarcinoma of the stomach at Taipei Veterans General Hospital. Among them, 419 patients had recurrence; they were divided into early recurrence (<2 years) and late recurrence (≥2 years). The clinicopathological characteristics, survival time after recurrence, and recurrence patterns were compared between the two groups.
Results: Multivariate analysis showed that stage III gastric cancer patients with early recurrence had larger tumors and more lymph node metastasis than patients with late recurrence, while no difference between early and late recurrence was observed in stage I and II patients. Early recurrence was associated with more distant metastasis than was late recurrence. Patients with advanced TNM stage tended to die within 2 years after recurrence.
Conclusions: Gastric cancer patients with larger tumors and more lymph node metastasis tended to have early recurrence, especially stage III patients. Advanced TNM stage was associated with early cancer death after recurrence.
Machine Learning Prediction of Early Recurrence in Gastric Cancer: A Nationwide Real-World Study.
Zhang X, Huang Z, Wu J, Liu X, Xie R, Wu Y Ann Surg Oncol. 2024; 32(4):2637-2650.
PMID: 39738899 DOI: 10.1245/s10434-024-16701-y.
Cao M, Hu C, Pan S, Zhang Y, Yu P, Zhang R World J Surg Oncol. 2024; 22(1):21.
PMID: 38243254 PMC: 10797937. DOI: 10.1186/s12957-023-03294-1.
Tian H, Liu Z, Zhang Z, Zhang L, Zong Z, Liu J J Inflamm Res. 2023; 16:4373-4388.
PMID: 37808954 PMC: 10557981. DOI: 10.2147/JIR.S412033.
A liquid biopsy signature for predicting early recurrence in patients with gastric cancer.
Okuno K, Watanabe S, Roy S, Kanda M, Tokunaga M, Kodera Y Br J Cancer. 2023; 128(6):1105-1116.
PMID: 36631634 PMC: 10006424. DOI: 10.1038/s41416-022-02138-1.
Influence of the Microbiome Metagenomics and Epigenomics on Gastric Cancer.
Mathebela P, Damane B, Mulaudzi T, Mkhize-Khwitshana Z, Gaudji G, Dlamini Z Int J Mol Sci. 2022; 23(22).
PMID: 36430229 PMC: 9693604. DOI: 10.3390/ijms232213750.